Miłosz Włodarczyk

Miłosz Włodarczyk

Auto-generated profile, based on publicly available information

Miłosz Włodarczyk

Student’s Scientific Association at the 1st Chair and Department of Oncological Gynecology and Gynecology, Medical University of Lublin, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2026 in Medical Science Pulse
Verified
Journal Article
Closed access
Aleksandra DomańskaAleksandra Domańska
Aleksandra Domańska
NPNatalia Pijas
Natalia Pijas
DWDamian Wach
Damian Wach
MWMiłosz Włodarczyk
Miłosz Włodarczyk
PWPatrycja Wójcikiewicz
Patrycja Wójcikiewicz
KKKrzysztof Jerzy Kułak
Krzysztof Jerzy Kułak
Background: Ovarian cancer remains one of the most lethal gynecologic malignancies, ranking eighth in both incidence and mortality among women. Its asymptomatic early course and nonspecific symptoms often lead to late-stage diagnosis and a poor prognosis.Aim of the study: The aim of this article is to present the current status of immunotherapy in the treatment of ovarian cancer.Material and methods: A narrative review of the available literature was conducted, focusing on recent trials and studies evaluating immunotherapeutic approaches in ovarian cancer.Results: Standard treatment for ovarian cancer includes cytoreductive surgery followed by platinum-based chemotherapy; however, recurrence and platinum resistance remain major clinical challenges. In recent years, immunotherapy has emerged as an actively investigated treatment strategy, particularly in platinum-resistant disease. Various strategies are under investigation, including immune checkpoint inhibitors, CAR T-cell therapies, and oncolytic viruses. PD-1/PD-L1 inhibitors have shown potential efficacy, especially in tumors expressing PD-L1, which may serve as a predictive biomarker for treatment response.Conclusions: Despite promising research results, the clinical benefits of immunotherapy in ovarian cancer remain limited. Future studies should focus on identifying reliable predictive biomarkers, optimizing combination therapies, and improving treatment efficacy while maintaining an acceptable safety profile.